CA3254365A1 - POLYMORPHIC FORMS OF ATICAPRANT INTENDED FOR USE IN THE TREATMENT OF MAJOR DEPRESSION - Google Patents

POLYMORPHIC FORMS OF ATICAPRANT INTENDED FOR USE IN THE TREATMENT OF MAJOR DEPRESSION

Info

Publication number
CA3254365A1
CA3254365A1 CA3254365A CA3254365A CA3254365A1 CA 3254365 A1 CA3254365 A1 CA 3254365A1 CA 3254365 A CA3254365 A CA 3254365A CA 3254365 A CA3254365 A CA 3254365A CA 3254365 A1 CA3254365 A1 CA 3254365A1
Authority
CA
Canada
Prior art keywords
aticaprant
crystalline form
treatment
amorphous
placebo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3254365A
Other languages
English (en)
French (fr)
Inventor
Philippe Fernandes
Mark Schmidt
Vanina Popova
Adam Savitz
Rama Melkote
Wayne C. Drevets
Srihari Gopal
Darrel Pemberton
Chakradhar Lagishetty
Iva Kezic
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of CA3254365A1 publication Critical patent/CA3254365A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3254365A 2022-03-07 2023-03-06 POLYMORPHIC FORMS OF ATICAPRANT INTENDED FOR USE IN THE TREATMENT OF MAJOR DEPRESSION Pending CA3254365A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263317475P 2022-03-07 2022-03-07
US63/317,475 2022-03-07
PCT/IB2023/052088 WO2023170550A1 (en) 2022-03-07 2023-03-06 Polymorph forms of aticaprant for use in treating major depressive disorder

Publications (1)

Publication Number Publication Date
CA3254365A1 true CA3254365A1 (en) 2023-09-14

Family

ID=85706849

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3254365A Pending CA3254365A1 (en) 2022-03-07 2023-03-06 POLYMORPHIC FORMS OF ATICAPRANT INTENDED FOR USE IN THE TREATMENT OF MAJOR DEPRESSION

Country Status (14)

Country Link
US (3) US11998524B2 (https=)
EP (1) EP4489747A1 (https=)
JP (1) JP2025508051A (https=)
KR (1) KR20240156409A (https=)
CN (1) CN119156211A (https=)
AU (1) AU2023232536A1 (https=)
CA (1) CA3254365A1 (https=)
CL (1) CL2024002627A1 (https=)
CO (1) CO2024012158A2 (https=)
IL (1) IL315409A (https=)
JO (1) JOP20240197A1 (https=)
MX (1) MX2024010980A (https=)
TW (1) TW202345796A (https=)
WO (1) WO2023170550A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
WO2023170554A1 (en) 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. Compositions comprising aticaprant

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457208A (en) 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
TR200103237T2 (tr) 1999-05-12 2002-04-22 F. Hoffmann-La Roche Ag İmidazodiazepin türevi
US20020052365A1 (en) 2000-10-05 2002-05-02 Mohler Hanns Selective anxiolytic therapeutic agents
JP2004518654A (ja) 2000-12-21 2004-06-24 ザ マクレーン ホスピタル コーポレーション 鬱病の治療法
US6974824B2 (en) 2001-01-08 2005-12-13 Research Triangle Institute Kappa opioid receptor ligands
DE60319812T2 (de) 2002-03-28 2009-04-23 Wisys Technology Foundation, Inc., Madison Angstlösende wirkstoffe mit verminderten beruhigenden und ataktischen nebenwirkungen
KR101025633B1 (ko) 2002-09-19 2011-03-30 일라이 릴리 앤드 캄파니 오피오이드 수용체 안타고니스트로서의 디아릴 에테르
ATE406360T1 (de) 2003-03-07 2008-09-15 Lilly Co Eli Antagonisten der opioidrezeptoren
EP1613597B1 (en) 2003-03-07 2007-11-07 Eli Lilly and Company 6-substituted nicotinamide derivatives as opioid receptor antagonists
CA2549009A1 (en) 2003-12-12 2005-07-07 Eli Lilly And Company Opioid receptor antagonists
ES2390459T3 (es) 2003-12-22 2012-11-13 Eli Lilly And Company Antagonistas de receptores de opioides
DE602005022572D1 (de) 2004-03-12 2010-09-09 Lilly Co Eli Antagonisten des opioidrezeptors
EP1729759A4 (en) 2004-03-12 2008-04-02 Mclean Hospital Corp SALVINORINE DERIVATIVES AND ITS USES
ATE399164T1 (de) 2004-03-12 2008-07-15 Lilly Co Eli Antagonisten des opioidrezeptors
DE602005012380D1 (de) 2004-03-15 2009-03-05 Lilly Co Eli 4-(5-(aminomethyl)-indol-1-ylmethyl)benzamidderivate und verwandte verbindungen als opioidrezeptorantagonisten zur behandlung von fettleibigkeit
EP1735268B1 (en) 2004-03-15 2012-02-15 Eli Lilly And Company Opioid receptor antagonists
WO2007067714A2 (en) 2005-12-08 2007-06-14 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
JP5128578B2 (ja) 2006-04-04 2013-01-23 エモディス ゲーエムベーハー 解離性障害の治療のためのκ−オピオイド受容体アンタゴニスト含有組成物の利用
EP2049481A2 (en) 2006-08-09 2009-04-22 SmithKline Beecham Corporation Novel compounds as antagonists or inverse agonists for opioid receptors
EP2054383A2 (en) 2006-08-09 2009-05-06 SmithKline Beecham Corporation Novel compounds as antagonists or inverse agonists at opioid receptors
KR20090051778A (ko) 2006-09-08 2009-05-22 화이자 프로덕츠 인코포레이티드 다이아릴 에터 유도체 및 이의 용도
JP5345637B2 (ja) 2008-01-22 2013-11-20 イーライ リリー アンド カンパニー κ選択的オピオイド受容体アンタゴニスト
WO2012016569A1 (en) 2010-08-05 2012-02-09 Conrig Pharma Aps Deuterated tandospirone derivatives as 5-ht1a receptor agonists
ES2631607T3 (es) 2011-12-09 2017-09-01 Research Triangle Institute, International 4-Arilpiperazinas 1-sustituidas como antagonistas del receptor opioide kappa
ES2694352T3 (es) 2013-12-20 2018-12-20 H. Lundbeck A/S Uso de un antagonista del receptor opioide con actividad kappa, y vortioxetina para el tratamiento del trastorno depresivo con características melancólicas
WO2016156396A1 (en) 2015-03-30 2016-10-06 University Of Innsbruck Diphenethylamine derivatives which are inter alia useful as analgesics and methods for their production
US10709685B2 (en) 2015-05-28 2020-07-14 Georgetown University Use of methadone metabolites for treatment of anxiety and depression
EP3468540A4 (en) 2016-06-13 2020-03-18 Board Of Regents Of the University Of Texas System PHARMACEUTICAL COMPOSITIONS AND METHOD FOR TREATING PAIN
US20190240293A1 (en) 2016-07-26 2019-08-08 Flagship Pioneering Innovations V, Inc. Neuromodulating compositions and related therapeutic methods for the treatment of cancer by modulating an anti-cancer immune response
US11292783B2 (en) 2016-09-16 2022-04-05 Research Triangle Institute Substituted 1,2,3,4-tetrahydroisoquinolines as kappa opioid antagonists
US10316021B2 (en) 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
AU2018234931B2 (en) 2017-03-17 2022-05-26 Blackthorn Therapeutics, Inc. Kappa opioid receptor antagonists and products and methods related thereto
PH12018000077B1 (en) 2017-07-05 2021-07-09 Frimline Private Ltd A pharmaceutical composition for neuropathic pain
US20190255036A1 (en) 2018-02-16 2019-08-22 Alexander Kariman Compound and method for reducing neuropathic pain and depression
JP7416751B2 (ja) 2018-03-23 2024-01-17 ユニバーシティ オブ カンザス 環状テトラペプチド類似体
US11491144B2 (en) 2018-03-30 2022-11-08 The Florida State University Research Foundation, Incorporated Methods of treating fragile X mental retardation syndrome
EP3870030A4 (en) 2018-10-23 2022-08-03 Blackthorn Therapeutics, Inc. SYSTEMS AND METHODS FOR SCREENING, DIAGNOSIS AND STRATIFICATION OF PATIENTS
US20200171025A1 (en) 2018-11-29 2020-06-04 Srinivasa Rao Parella Pharmaceutical composition comprising brexpiprazole and process for preparation thereof
US11266627B1 (en) * 2021-05-04 2022-03-08 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
CN114195693A (zh) * 2020-09-17 2022-03-18 广东东阳光药业有限公司 一种酰胺化合物的晶型及其制备方法
PH12023552963A1 (en) * 2021-05-04 2024-03-11 Janssen Pharmaceuticals Inc Compositions and methods for the treatment of depression
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
AU2023231493A1 (en) 2022-03-07 2024-10-24 Janssen Pharmaceuticals, Inc. Pure forms of crystalline aticaprant
WO2023170554A1 (en) 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. Compositions comprising aticaprant

Also Published As

Publication number Publication date
AU2023232536A1 (en) 2024-10-24
US20230277499A1 (en) 2023-09-07
US11998524B2 (en) 2024-06-04
IL315409A (en) 2024-11-01
CL2024002627A1 (es) 2025-01-24
CN119156211A (zh) 2024-12-17
JOP20240197A1 (ar) 2024-09-05
KR20240156409A (ko) 2024-10-29
US12171743B2 (en) 2024-12-24
WO2023170550A1 (en) 2023-09-14
CO2024012158A2 (es) 2024-09-30
JP2025508051A (ja) 2025-03-21
EP4489747A1 (en) 2025-01-15
US20240316003A1 (en) 2024-09-26
US20250325515A1 (en) 2025-10-23
MX2024010980A (es) 2024-12-06
TW202345796A (zh) 2023-12-01

Similar Documents

Publication Publication Date Title
US20250325515A1 (en) Forms Of Aticaprant
CN117771252A (zh) 神经活性甾类及其使用方法
EP4489748A1 (en) Pure forms of crystalline aticaprant
CA3219079A1 (en) Compositions and methods for the treatment of depression
US12201610B2 (en) Compositions comprising aticaprant
TW200843763A (en) 5-HTP combination therapy
JP7766026B2 (ja) 自閉症スペクトラム障害の症状を治療する方法
US12171758B1 (en) Crystalline salt forms of kappa opioid receptor antagonist and products and methods related thereto
JP2016506918A (ja) イソメテプテン異性体
AU2020242302B2 (en) Methods of treating borderline personality disorder
EP3941465B1 (en) Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat
EA053068B1 (ru) Полиморфные формы атикапранта для применения при лечении большого депрессивного расстройства
WO2024173873A2 (en) Compounds, compositions, and methods for treating, ameliorating, and/or preventing pain
JP2026505778A (ja) 産後うつ病の処置における５－ｍｅｏ－ｄｍｔの使用
JP2025511072A (ja) 産後うつ病の処置に使用するための５－ＭｅＯ－ＤＭＴ
HK40067920B (en) Vafidemstat for the treatment of non-aggressive symptoms of borderline personality disorder
HK40067920A (en) Vafidemstat for the treatment of non-aggressive symptoms of borderline personality disorder
TW200938189A (en) [2-(6-flouro-1H-indol-3-ylsulfanyl)benzyl]methyl amine for the treatment of affective disorders

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240905

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250204

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20250205

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250205

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250205

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250218

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED

Effective date: 20250224

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250224

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250819

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260203

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260203